10x Genomics (TXG) Earnings: What to Expect Tomorrow

As 10x Genomics (TXG) prepares to report its earnings for the fourth quarter and full year of 2024, investors and analysts are eagerly awaiting the results. The company, a leader in single-cell and spatial biology, has been making significant strides in its product portfolio and strategic partnerships. With a market cap of $1.46 billion and an enterprise value of $1.15 billion, 10x Genomics has shown strong revenue growth, increasing by 19.81% in 2023 compared to the previous year. However, the company also reported a loss of -$255.10 million in 2023, which was 53.7% more than in 2022.